Tenofovir Disoproxil Orotate

乳清酸替诺福韦二吡呋酯

Report date: 2025/03/18 14:31:32

Base Information

Drug NameTenofovir Disoproxil Orotate

Drug Alias Name替诺福韦酯乳清酸DA-2802

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues

Mechanisms of ActionHuman immunodeficiency virus type 1 reverse transcriptase inhibitorsHBV DNA Polymerase inhibitors

TargetsHuman immunodeficiency virus type 1 reverse transcriptaseHBV DNA Polymerase

Therapy Area/IndicationsHepatitis B, ChronicHIV Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesSouth Korea

CombinationsNo

Global Highest StatusPending (Phase 3 Clinical)

Highest Status in ChinaN/A

China Registration ClassN/A

Active CompaniesN/A

Active IndicationsN/A

Inactive IndicationsHepatitis B, ChronicHIV Infections

ATC CodeN/A